Diagnosis of Multiple Cancer and Monitoring of Minimal Residual Tumors After Treatment Using Blood and High-Sensitivity Genetic Analysis Techniques

Launched by YONSEI UNIVERSITY · Jun 15, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new blood test that aims to detect several types of cancer early and to monitor patients after treatment to see if any cancer remains or returns. The test looks for tiny pieces of tumor DNA circulating in the blood, which can give doctors important information about the presence and behavior of cancer without needing invasive procedures like biopsies. This method could help catch cancers like ovarian, lung, pancreatic, colorectal, esophageal, breast, kidney, bladder, and stomach cancer earlier and improve follow-up care after surgery or chemotherapy.

People eligible to join this study include adults aged 19 and older who have been diagnosed with one of the cancers listed above and are undergoing or have undergone treatment. Healthy individuals without cancer but with benign (non-cancerous) conditions like gallstones or polyps, or those having routine medical check-ups, can also participate as a comparison group. Participants will provide blood samples before and after treatment and during follow-up visits, while healthy volunteers will give a single blood sample. The study aims to see how well this blood test works compared to traditional methods, with hopes that it will offer a less invasive, more accurate way to detect and monitor cancer, ultimately helping patients receive better and more timely care.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 19 years
• • Voluntarily agreed to participate and provided informed consent
• • Able to donate blood without health risks
• • Underwent or is scheduled to undergo surgery or chemotherapy for therapeutic purposes for cancer (for cancer group)
• • Diagnosed with one of the following cancers: ovarian, lung, pancreatic, colorectal, esophageal, breast, bladder, kidney, or gastric cancer
• • Control group: asymptomatic individuals with gallstones or benign polyps, or subjects undergoing routine health screenings
• • Control group must have confirmed benign findings through imaging (ultrasound, CT, LDCT, colonoscopy)
• Exclusion Criteria:
• • Age \< 19 years
• • Patients with mental retardation or severe psychiatric disorders affecting informed consent
• • History of HIV, HTLV, or syphilis infection
• • History of other malignancy within 5 years (for cancer group)
• • No somatic mutation detected in tumor or pre-treatment cfDNA (for cancer group)
• • Control group with any past or current cancer diagnosis
• • Control group with high-grade adenoma, symptomatic gallstones/polyps, or recent (\<6 months) abdominal surgery
• • Pregnant or breastfeeding women
• • Any other reason deemed inappropriate by the investigator